Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of Deferred ChargesAmortization of GoodwillAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionDivestmentsDividends Paid - CommonFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

AdaptHealth (AHCO) Capital Expenditures (2019 - 2025)

AdaptHealth has reported Capital Expenditures over the past 7 years, most recently at -$212.6 million for Q4 2025.

  • Quarterly results put Capital Expenditures at -$212.6 million for Q4 2025, down 374.9% from a year ago — trailing twelve months through Dec 2025 was $65.9 million (down 78.47% YoY), and the annual figure for FY2025 was $65.9 million, down 78.47%.
  • Capital Expenditures for Q4 2025 was -$212.6 million at AdaptHealth, down from $94.2 million in the prior quarter.
  • Over the last five years, Capital Expenditures for AHCO hit a ceiling of $305.0 million in Q4 2023 and a floor of -$212.6 million in Q4 2025.
  • Median Capital Expenditures over the past 5 years was $68.7 million (2021), compared with a mean of $37.4 million.
  • Biggest five-year swings in Capital Expenditures: soared 11165.44% in 2021 and later crashed 2234.86% in 2022.
  • AdaptHealth's Capital Expenditures stood at $1.2 million in 2021, then crashed by 2234.86% to -$26.6 million in 2022, then soared by 1244.7% to $305.0 million in 2023, then tumbled by 74.64% to $77.3 million in 2024, then plummeted by 374.9% to -$212.6 million in 2025.
  • The last three reported values for Capital Expenditures were -$212.6 million (Q4 2025), $94.2 million (Q3 2025), and $88.7 million (Q2 2025) per Business Quant data.